Medicalsystem Biotechnology Past Earnings Performance
Past criteria checks 5/6
Medicalsystem Biotechnology has been growing earnings at an average annual rate of 29.2%, while the Biotechs industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 9.3% per year. Medicalsystem Biotechnology's return on equity is 9.6%, and it has net margins of 14.1%.
Key information
29.2%
Earnings growth rate
27.6%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -9.3% |
| Return on equity | 9.6% |
| Net Margin | 14.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Medicalsystem Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,876 | 264 | 450 | 149 |
| 31 Dec 23 | 1,886 | 257 | 445 | 150 |
| 30 Sep 23 | 2,059 | 225 | 442 | 165 |
| 30 Jun 23 | 2,175 | 227 | 484 | 169 |
| 31 Mar 23 | 2,403 | 200 | 470 | 175 |
| 01 Jan 23 | 2,489 | 199 | 516 | 172 |
| 30 Sep 22 | 2,431 | 210 | 505 | 167 |
| 30 Jun 22 | 2,421 | 193 | 508 | 156 |
| 31 Mar 22 | 2,298 | 174 | 502 | 154 |
| 31 Dec 21 | 2,252 | 179 | 497 | 151 |
| 30 Sep 21 | 2,274 | 173 | 463 | 148 |
| 30 Jun 21 | 2,304 | 207 | 464 | 148 |
| 31 Mar 21 | 2,392 | 209 | 458 | 142 |
| 31 Dec 20 | 2,302 | 299 | 447 | 135 |
| 30 Sep 20 | 2,529 | -466 | 485 | 138 |
| 30 Jun 20 | 2,726 | -463 | 539 | 137 |
| 31 Mar 20 | 2,883 | -466 | 544 | 127 |
| 31 Dec 19 | 3,133 | -560 | 572 | 128 |
| 30 Sep 19 | 3,141 | 248 | 588 | 131 |
| 30 Jun 19 | 3,203 | 243 | 548 | 114 |
| 31 Mar 19 | 3,173 | 242 | 544 | 113 |
| 31 Dec 18 | 3,135 | 241 | 544 | 110 |
| 30 Sep 18 | 3,171 | 264 | 503 | 100 |
| 30 Jun 18 | 2,948 | 260 | 446 | 142 |
| 31 Mar 18 | 2,921 | 257 | 484 | 116 |
| 31 Dec 17 | 2,584 | 230 | 464 | 93 |
| 30 Sep 17 | 2,145 | 198 | 483 | 59 |
| 30 Jun 17 | 1,765 | 189 | 468 | 0 |
| 31 Mar 17 | 1,201 | 183 | 395 | 0 |
| 31 Dec 16 | 1,055 | 177 | 355 | 0 |
| 30 Sep 16 | 863 | 190 | 279 | 0 |
| 30 Jun 16 | 756 | 180 | 255 | 0 |
| 31 Mar 16 | 708 | 167 | 241 | 0 |
| 31 Dec 15 | 683 | 161 | 219 | 0 |
| 30 Sep 15 | 650 | 149 | 225 | 0 |
| 30 Jun 15 | 648 | 149 | 200 | 0 |
| 31 Mar 15 | 632 | 145 | 178 | 0 |
| 31 Dec 14 | 598 | 138 | 160 | 0 |
| 31 Dec 13 | 432 | 104 | 118 | 0 |
Quality Earnings: 300439 has high quality earnings.
Growing Profit Margin: 300439's current net profit margins (14.1%) are higher than last year (8.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300439's earnings have grown significantly by 29.2% per year over the past 5 years.
Accelerating Growth: 300439's earnings growth over the past year (31.9%) exceeds its 5-year average (29.2% per year).
Earnings vs Industry: 300439 earnings growth over the past year (31.9%) exceeded the Biotechs industry -2.6%.
Return on Equity
High ROE: 300439's Return on Equity (9.6%) is considered low.